Orient Pharma Co., Ltd. (TPEX:4166)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Overseas Business Division		59.92M	39.02M	63.07M	45.91M	10.45M
Overseas Business Division Growth		53.57%	-38.14%	37.37%	339.39%	21.20%
Plant Operating Department		1.16B	847.11M	446.27M	416.30M	400.42M
Plant Operating Department Growth		37.28%	89.82%	7.20%	3.97%	16.43%
Pharmaceutical Operations		-	3.78M	2.52M	1.13M	1.14M
Pharmaceutical Operations Growth		-	50.24%	122.83%	-0.88%	14.57%
Total		1.22B	889.91M	511.86M	463.34M	412.01M
Total Growth		37.41%	73.86%	10.47%	12.46%	16.54%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan		826.45M	679.80M	253.78M	323.43M	412.01M
Taiwan Growth		21.57%	167.88%	-21.54%	-21.50%	16.54%
United States		325.38M	178.49M	216.26M	108.62M	-
United States Growth		82.30%	-17.46%	99.09%	-	-
Philippines		13.25M	23.81M	-	-	-
Philippines Growth		-44.34%	-	-	-	-
China		34.43M	18.00K	37.92M	17.14M	-
China Growth		191155.56%	-99.95%	121.16%	-	-
Others		23.31M	7.80M	3.91M	14.15M	-
Others Growth		199.00%	99.23%	-72.34%	-	-
Total		1.22B	889.91M	511.86M	463.34M	412.01M
Total Growth		37.41%	73.86%	10.47%	12.46%	16.54%

Source: S&P Global Market Intelligence.